Tadashi Sofue

Tadashi Sofue


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTadashi Sofue
Tadashi Sofue
Naoki NakagawaNaoki Nakagawa
Naoki Nakagawa
EKEiichiro Kanda
Eiichiro Kanda
HNHajime Nagasu
Hajime Nagasu
KMKunihiro Matsushita
Kunihiro Matsushita
NKNaoki Kashihara
Naoki Kashihara
The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalence of anemia and the utilization rate of erythropoiesis-stimulating agents (ESAs) in Japanese patients with CKD. In total, 31,082 adult outpatients with estimated glomerular filtration rates of 5–60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively. The mean (standard deviation) hemoglobin level of male patients was 13.6 (1.9) g/dl, which was significantly higher than the mean hemoglobin level of female patients (12.4 (1.6) g/dl). The mean (standard deviation) hemoglobin levels were 11.4 (2.1) g/dl in patients with CKD stage G4 and 11.2 (1.8) g/dl in patients with CKD stage G5. The prevalences of anemia were 40.1% in patients with CKD stage G4 and 60.3% in patients with CKD stage G5. Logistic regression analysis showed that diagnoses of CKD stage G3b (adjusted odds ratio [95% confidence interval]: 2.32 [2.09–2.58]), G4 (5.50 [4.80–6.31]), and G5 (9.75 [8.13–11.7]) were associated with increased prevalence of anemia. The utilization rates of ESAs were 7.9% in patients with CKD stage G4 and 22.4% in patients with CKD stage G5. We determined the prevalence of anemia and utilization rate of ESAs in Japanese patients with CKD using data from a nationwide cohort study.

24 August 2018 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
HOHideyo Oguchi
Hideyo Oguchi
MTMakoto Tsujita
Makoto Tsujita
MYMasahiko Yazawa
Masahiko Yazawa
TKTakehiko Kawaguchi
Takehiko Kawaguchi
JHJunichi Hoshino
Junichi Hoshino
TSTadashi Sofue
Tadashi Sofue

15 October 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTadashi Sofue
Tadashi Sofue
Naoki NakagawaNaoki Nakagawa
Naoki Nakagawa
EKEiichiro Kanda
Eiichiro Kanda
HNHajime Nagasu
Hajime Nagasu
KMKunihiro Matsushita
Kunihiro Matsushita
NKNaoki Kashihara
Naoki Kashihara
The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD. In total, 35,508 adult outpatients with estimated glomerular filtration rates of 5–60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively. Logistic regression analysis showed that prevalence of hyperuricemia was associated with CKD stages G3b (adjusted odds ratio [95% confidence interval]: 2.12 [1.90–2.37]), G4 (4.57 [3.92–5.32]), and G5 (2.25 [1.80–2.80]). The respective prevalences of hyponatremia, hypercalcemia, hyperphosphatemia, and narrower difference between serum sodium and chloride concentrations were elevated in patients with CKD stages G3b, G4, and G5, compared with those prevalences in patients with CKD stage G3a. The prevalences of hyperkalemia were 8.3% and 11.6% in patients with CKD stages G4 and G5, respectively. In patients with CKD stage G5, the proportions of patients with optimal ranges of serum uric acid, potassium, corrected calcium, and phosphate were 49.6%, 73.5%, 81.9%, and 56.1%, respectively. We determined the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD using data from a nationwide cohort study.

1 November 2013 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
TSTadashi Sofue
Tadashi Sofue
MIMasashi Inui
Masashi Inui
THTaiga Hara
Taiga Hara
MMMasahiro Moritoki
Masahiro Moritoki
SNSatoshi Nishioka
Satoshi Nishioka
MKMasakazu Kohno
Masakazu Kohno
Introduction: Latent mesangial immunoglobulin A (IgA) deposition in the donated kidney has been investigated in the context of kidney transplantation. However, few studies have examined the impact of mesangial expansion accompanied with IgA deposition. Therefore, we investigated the effects of latent IgA deposition and mesangial expansion on transplant prognosis following living‐donor kidney transplantation.Methods: We retrospectively analyzed 68 consecutive adult living‐donor kidney transplantations performed at Kagawa University Hospital. Biopsies were performed at pre‐implantation and at one yr after transplantation.Results: Twenty kidneys exhibited latent IgA deposition in pre‐implantation biopsies, including 14 with mesangial expansion. Latent IgA deposition was not associated with renal function or donor urinalysis after donation, irrespective of mesangial expansion. Latent IgA deposition was not significantly associated with graft survival rate, allograft function, abnormal urinalysis, or the recurrence of IgA nephropathy, irrespective of mesangial expansion. At one yr after transplantation, IgA deposition had disappeared in 14/20 allografts. Estimated glomerular function rate >40 mL/min/1.73 m2 was significantly associated with the disappearance of IgA deposition.Conclusions: The present study showed that latent IgA deposition from the donor kidney, irrespective of mesangial expansion, does not affect transplant prognosis following living‐donor kidney transplantation.

1 May 2012 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
TSTadashi Sofue
Tadashi Sofue
HKHideyasu Kiyomoto
Hideyasu Kiyomoto
HKHiroyuki Kobori
Hiroyuki Kobori
MUMaki Urushihara
Maki Urushihara
YNYoko Nishijima
Yoko Nishijima
ANAkira Nishiyama
Akira Nishiyama
Background. Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of mi

13 July 2012 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
TSTadashi Sofue
Tadashi Sofue
MIMasashi Inui
Masashi Inui
HKHideyasu Kiyomoto
Hideyasu Kiyomoto
MMMasahiro Moritoki
Masahiro Moritoki
SNSatoshi Nishioka
Satoshi Nishioka
MKMasakazu Kohno
Masakazu Kohno
Background: Donor shortage is a serious problem worldwide and it is now debated whether kidneys from marginal donors are suitable for renal transplantation. Recent studies have shown that the findings of preimplantation kidney biopsy are useful to evaluate vasculopathy in the donated kidney, and may predict transplant outcomes in deceased- donor kidney transplantation. However, few studies have focused on the pathological findings of preimplantation biopsy in living-donor kidney transplantation. Therefore, we investigated whether arteriosclerotic vasculopathy in living-donor kidneys at the time of transplantation predicts the recipient’s kidney function (allograft function) later in life. Methods: We retrospectively analyzed 75 consecutive adult living-donor kidney transplants performed at Kagawa University Hospital. Renal arteriosclerotic vasculopathy was defined according to the presence of fibrous intimal thickening in the interlobular artery. Results: Forty-one kidneys exhibited mild arteriosclerotic vasculopathy on preimplantation kidney biopsies. The decreases in estimated glomerular filtration rate after donation were similar in donors with or without renal arteriosclerotic vasculopathy. Pre-existing arteriosclerotic vasculopathy did not affect graft survival rate, patient survival rate or the incidence of complications. Recipients of kidneys with arteriosclerotic vasculopathy had lower allograft function at 1 and 3 years after transplantation than the recipients of arteriosclerosis-free kidneys with or without donor hypertension. In multivariate analysis, fibrous intimal thickening on preimplantation biopsy was predictive of reduced allograft function at 1 year after transplantation. Conclusions: The present study demonstrated that mild arteriosclerotic vasculopathy in the donated kidney is an important pathological factor that reflects future impaired function of renal allografts from marginal donors.